The European Commission approved Novartis drug Lucentis as first effective anti-VEGF treatment for myopic choroidal neovascularization

Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of … Read the full press release →